Condition: Indolent Systemic Mastocytosis · Sponsor: Blueprint Medicines Corporation
This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
This description comes directly from the study's public registry record.
Blueprint Medicines · 1-888-258-7768 · medinfo@blueprintmedicines.com
Blueprint Medicines, EU Contact · +31 85 064 4001 · medinfoeurope@blueprintmedicines.com
Always discuss trial participation with your own doctor first.
| Brigham and Women's Allergy and Clinical Immunology, Mass General Brigham Healthcare Center (Chestnut Hill) | Chestnut Hill, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07264959